| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7498343 | JANSSEN THERAP | Mycobacterial inhibitors |
Dec, 2026
(3 years from now) | |
| US8546428 | JANSSEN THERAP | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Mar, 2029
(5 years from now) | |
Sirturo is owned by Janssen Therap.
Sirturo contains Bedaquiline Fumarate.
Sirturo has a total of 2 drug patents out of which 0 drug patents have expired.
Sirturo was authorised for market use on 28 December, 2012.
Sirturo is available in tablet;oral dosage forms.
Sirturo can be used as treatment of pulmonary multi-drug resistant tuberculosis.
The generics of Sirturo are possible to be released after 19 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 27, 2027 |
Drugs and Companies using BEDAQUILINE FUMARATE ingredient
Market Authorisation Date: 28 December, 2012
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
Dosage: TABLET;ORAL
SIRTURO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic